Rare diseases
Investigational molecules
Locations
296 conditions with trials, the busiest first
591 trials across Europe, recruiting first
Study on Pembrolizumab for Patients with Resectable Metastases from Kidney Cancer
ItalyStudy on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
BelgiumStudy on the Safety and Effects of Temferon for Patients with Metastatic Renal Cell Carcinoma Using a Drug Combination
ItalyStudy of Axitinib and Pembrolizumab for Patients with Advanced or Metastatic Papillary Renal Cell Carcinoma
FranceStudy of Oncobax-AK with Immunotherapy for Patients with Advanced Non-Small Cell Lung Cancer or Renal Cell Carcinoma
BelgiumStudy of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer
GreeceStudy of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG
BelgiumStudy of Dabrafenib and Drug Combination for Patients with Metastatic Non-Clear Cell Kidney Cancer
DenmarkStudy on Obinutuzumab vs. Rituximab for Children with Steroid-Dependent and Frequent Relapsing Nephrotic Syndrome
FranceStudy on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment
GermanyStudy on the Effectiveness and Safety of Pegcetacoplan for Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
AustriaStudy on the Safety and Effectiveness of Pegcetacoplan for Patients with Post-Transplant Recurrence of C3 Glomerulopathy or Immune Complex Membranoproliferative Nephritis
AustriaThe therapies tested most often in Renal and urinary disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
